NextCure, Inc. — Director's Dealing 2019

May 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-13

Reporting Person: CANAAN X L.P. (10% Owner)
Reporting Person: Canaan Partners X LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-13	Common Stock	C	445866	—	Acquired	445866	Direct
2019-05-13	Common Stock	C	743110	—	Acquired	1188976	Direct
2019-05-13	Common Stock	C	729599	—	Acquired	1918575	Direct
2019-05-13	Common Stock	C	285867	—	Acquired	2204442	Direct
2019-05-13	Common Stock	P	50000	$15.00	Acquired	2254442	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-13	Series A-1 Preferred Stock	$	C	3582000	Disposed		Common Stock (445866)	Direct
2019-05-13	Series A-2 Preferred Stock	$	C	5970000	Disposed		Common Stock (743110)	Direct
2019-05-13	Series A-3 Preferred Stock	$	C	5861455	Disposed		Common Stock (729599)	Direct
2019-05-13	Series B-1 Preferred Stock	$	C	2296605	Disposed		Common Stock (285867)	Direct

Footnotes

F1: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2: The shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.